Related references
Note: Only part of the references are listed.Direct inhibition of RAS: Quest for the Holy Grail?
Russell Spencer-Smith et al.
SEMINARS IN CANCER BIOLOGY (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
Exceptionally high-affinity Ras binders that remodel its effector domain
John H. McGee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Guangming Chen et al.
MOLECULAR CANCER THERAPEUTICS (2018)
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
S-H Chen et al.
ONCOGENE (2018)
Targeting Ras with Macromolecules
Dehua Pei et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Engineering of a tumor cell-specific, cytosol-penetrating antibody with high endosomal escape efficacy
Ji-Sun Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Chiara Ambrogio et al.
CELL (2018)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling
Monique J. Kauke et al.
MOLECULAR CANCER THERAPEUTICS (2018)
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
Yeo Wool Kang et al.
CANCER LETTERS (2018)
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Camilo E. Quevedo et al.
NATURE COMMUNICATIONS (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Zbyslaw Sondka et al.
NATURE REVIEWS CANCER (2018)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-drivenSrc-Akt bypass signaling
Y-J Kim et al.
ONCOGENE (2017)
Biophysical properties of the clinical-stage antibody landscape
Tushar Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
Seung-Min Shin et al.
NATURE COMMUNICATIONS (2017)
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Sandrine Guillard et al.
NATURE COMMUNICATIONS (2017)
Exploring the Role of RGD-Recognizing Integrins in Cancer
Markus Nieberler et al.
CANCERS (2017)
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer
Xiao Zhao et al.
CANCER LETTERS (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Multivalent Small-Molecule Pan-RAS Inhibitors
Matthew E. Welsch et al.
CELL (2017)
The RAS-Effector Interaction as a Drug Target
Adam B. Keeton et al.
CANCER RESEARCH (2017)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Sai Krishna Athuluri-Divakar et al.
CELL (2016)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape
Ji-Sun Kim et al.
JOURNAL OF CONTROLLED RELEASE (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells by an enhanced split GFP complementation assay
Ji-sun Kim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis
Ye-Jin Kim et al.
JOURNAL OF CONTROLLED RELEASE (2015)
A novel screening method to assess developability of antibody-like molecules
Neeraj Kohli et al.
MABS (2015)
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
Alice Tzeng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway
Xiaolin Nan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Avnish Kapoor et al.
CELL (2014)
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Diane D. Shao et al.
CELL (2014)
Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy
Tae-Hwan Shin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells
Dong-Ki Choi et al.
MABS (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling
Marie Will et al.
CANCER DISCOVERY (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets
Martin L. Miller et al.
SCIENCE SIGNALING (2013)
TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers
Anurag Singh et al.
CELL (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
Luca Mologni et al.
PLOS ONE (2012)
An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway
Foster C. Gonsalves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Target mediated disposition of T84.66, a monoclonal anti-CEA antibody Application in the detection of colorectal cancer xenografts
Shweta R. Urva et al.
MABS (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity
Hye Young Yang et al.
MOLECULES AND CELLS (2009)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes
A Fujioka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Share Paper
